Catalyst Wire Dossier Catalyst Wire Dossier

HIVIG

anti-HIV immune serum globulin
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HIVIG, covering 2008-09-30 to 2008-09-30. Get the full timeline:

Most recent: Clinical Trial Update: A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT) [Phase 3]

See pricing